Durvalumab plus tremelimumab for the treatment of patients (pts) with refractory and progressive advanced thyroid carcinoma: A phase II multicohort trial (DUTHY / GETNE T1812)

被引：0
作者：
Hernando Cubero, J. [1 ]
Taberna Sanz, M. [2 ]
Carmona Bayonas, A. [3 ]
Iglesias, L. [4 ]
Grande, E. [5 ]
Trigo Perez, J. M. [6 ]
Grau, J. J. [7 ]
Lopez-Picazo, J. M. [8 ]
Castelo, B. [9 ]
Alonso Gordoa, T. [10 ]
Lorenzo, I. [11 ]
Casado Herraez, A. [12 ]
Ugidos, L. [13 ]
Munarriz, J. [14 ]
Lavernia, J. [15 ]
Capdevila, J. [1 ]
机构：
[1] Vall dHebron Univ Hosp, Med Oncol, Barcelona, Spain
[2] Hosp Duran & Reynals, ICO, Med Oncol, Lhospitalet De Llobregat, Spain
[3] Hosp Univ Morales Meseguer, Hematol & Med Oncol, Murcia, Spain
[4] Univ Hosp 12 Octubre, Oncol, Madrid, Spain
[5] MD Anderson Canc Ctr Madrid, Dept Med Oncol, Madrid, Spain
[6] Hosp Univ Virgen de la Victoria, Med Oncol, Malaga, Spain
[7] Hosp Clin Barcelona, Med Oncol, Barcelona, Spain
[8] Clin Univ Navarra, Med Oncol, Pamplona, Spain
[9] Hosp Univ La Paz, Med Oncol, Madrid, Spain
[10] Hosp Univ Ramon y Cajal, Med Oncol, Madrid, Spain
[11] Complejo Hosp Univ Vigo, Med Oncol, Vigo, Spain
[12] Hosp Clin Univ San Carlos, Dept Med Oncol, Madrid, Spain
[13] HM San Chinarro, Med Oncol, Madrid, Spain
[14] Hosp Gen Castellon, Med Oncol, Castellon de La Plana, Spain
[15] Hosp Gen Univ Valencia, Med Oncol, Valencia, Spain
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1872TiP
引用
收藏
页码：759 / 759
页数：1
相关论文
共 50 条
  • [31] Topotecan plus ifosfamide in patients with platinum refractory advanced non small cell lung carcinoma (NSCLC): A phase II trial
    Lorusso, V.
    Gebbia, V.
    Spada, M.
    Misino, A.
    Cassano, G.
    Brunetti, C.
    Germano, D.
    Nettis, G.
    Catalano, V.
    Galetta, D.
    Giampaglia, M.
    Misino, A.
    Colucci, G.
    [J]. ANNALS OF ONCOLOGY, 2005, 16 : 162 - 162
  • [32] A randomized phase II trial of durvalumab and tremelIMUmab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naive patients with CHolangio- and gallbladdEr Carcinoma (IMMUCHEC)
    Vogel, A.
    Boeck, S.
    Waidmann, O.
    Bitzer, M.
    Wenzel, P.
    Belle, S.
    Springfeld, C.
    Schulze, K.
    Weinmann, A.
    Lindig, U.
    Trautwein, C.
    Dechow, T.
    Lammert, F.
    Plentz, R.
    Koehne, C-H.
    Kunzmann, V.
    Maenz, M.
    Kirstein, M. M.
    Saborowski, A.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S563 - S563
  • [33] Phase I/II clinical trial of regorafenib plus durvalumab (MEDI4736) in patients with chemotherapy-refractory advanced biliary tract cancers.
    Al-Rajabi, Raed Moh'd Taiseer
    Kasi, Anup
    Baranda, Joaquina Celebre
    Saeed, Anwaar
    Li, Haoran
    Bruey, Collin
    Best, Shaun
    Phadnis, Milind A.
    Sun, Weijing
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS581 - TPS581
  • [34] Cabozantinib plus atezolizumab in locally advanced/metastatic adrenocortical carcinoma: Results from a multi-cohort basket phase II trial, CABATEN/GETNE-T1914.
    Grande, Enrique
    Vinuales, Marta Benavent
    Molina-Cerrillo, Javier
    Teule, Alex
    Jimenez-Fonseca, Paula
    Carmona-Bayonas, Alberto
    Lopez, Carlos
    Garcia-Carbonero, Rocio
    Hierro, Cinta
    Custodio, Ana
    Martinez-Trufero, Javier
    Llanos, Marta
    Sevilla, Isabel
    Hernando, Jorge
    Jimenez, Inmaculada Gallego
    Alonso-Gordoa, Teresa
    Gallego, Javier
    Capdevila, Jaume
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 1 - 1
  • [35] Responses to Cabozantinib plus Atezolizumab in a wide population of advanced and progressive neuroendocrine neoplasms (NENs): A prospective multi-cohort basket phase II Trial (CABATEN / GETNE-T1914)
    Molina-Cerrillo, J.
    Grande, E.
    Benavent, M.
    Garcia-Carbonero, R.
    Teule, A.
    Custodio, A.
    Jimenez-Fonseca, P.
    Hierro, C.
    Lopez, C.
    Sevilla, I
    Llanos, M.
    Capdevila, J.
    [J]. JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 245 - 245
  • [36] CCTG CO.26: Updated analysis and impact of plasma-detected microsatellite stability (MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma (rmCRC).
    Chen, Eric Xueyu
    Jonker, Derek J.
    Loree, Jonathan M.
    Kennecke, Hagen F.
    Berry, Scott R.
    Couture, Felix
    Ahmad, Chaudhary E.
    Goffin, John R.
    Kavan, Petr
    Harb, Mohammed
    Colwell, Bruce
    Samimi, Setareh
    Samson, Benoit
    Abbas, Tahir
    Aucoin, Nathalie
    Aubin, Francine
    Koski, Sheryl L.
    Wei, Alice Chia-chi
    Tu, Dongsheng
    O'Callaghan, Christopher J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [37] PAZONET: Results of a phase II trial of pazopanib as a sequencing treatment in progressive metastatic neuroendocrine tumors (NETs) patients (pts), on behalf of the Spanish task force for NETs (GETNE)-NCT01280201
    Grande Pulido, Enrique
    Castellano, Daniel E.
    Garcia-Carbonero, Rocio
    Teule, Alex
    Duran, Ignacio
    Fuster, Jose
    Sevilla, Isabel
    Escudero, P.
    Sastre, Javier
    Capdevila, Jaume
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC
    Peters, S.
    Antonia, S.
    Goldberg, S. B.
    Heymach, J. V.
    Kim, E. S.
    Nakagawa, K.
    Papadimitrakopoulou, V.
    Mukhopadhyay, P.
    McIntosh, S.
    Rizvi, N. A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S139 - S140
  • [39] Final results of the TALENT trial (GETNE1509): a prospective multicohort phase II study of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs).
    Capdevila, Jaume
    Fazio, Nicola
    Lopez, Carlos Lopez
    Teule, Alex
    Valle, Juan W.
    Tafuto, Salvatore
    Custodio, Ana B.
    Reed, Nicholas
    Raderer, Markus
    Grande, Enrique
    Garcia-Carbonero, Rocio
    Jimenez-Fonseca, Paula
    Alonso, Vicente
    Antonuzzo, Lorenzo
    Spallanzani, Andrea
    Berruti, Alfredo
    Sevilla, Isabel
    Munoa, Adelaida La Casta
    Hernando-Cubero, Jorge
    Ibrahim, Toni
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [40] Phase II trial of sorafenib plus doxorubicin (SD) in patients (Pts) with advanced hepatocellular carcinoma (HCC) after progression of disease (PD) on sorafenib (S).
    El Dika, Imane H.
    Capanu, Marinela
    Chou, Joanne F.
    Harding, James J.
    Hrabovsky, Anna D.
    Do, Richard K. G.
    Shia, Jinru
    Germino, Joseph
    O'Reilly, Eileen Mary
    Abou-Alfa, Ghassan K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345